Use of serine protease inhibitors in the treatment of skin diseases
AssigneesDermadis SA, Institut National de la Sante et de la Recherche Medicale
InventorsDavid Deperthes, Christoph Kundig, Alain Hovnanian, Celine Deraison
Life of this patent
Estimating the term…
Abstract
This invention relates to therapeutic compounds which are inhibitors of serine proteases, to pharmaceutical compositions thereof and to their use in the treatment of the human or animal body. More specifically, the present invention relates to a method for the treatment, diagnosis or prognosis of skin diseases comprising the administration to a subject in need thereof of a therapeutically effective amount of a Serine protease inhibitor.
Claims18
A method of treating a skin disease or undesirable skin condition selected from the group consisting of Netherton syndrome, atopic dermatitis, psoriasis, rosacea, pruritus, and peeling skin syndrome, comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition comprising a serine protease inhibitor comprising a reactive site loop (RSL) of the amino acid sequence of SEQ ID NO:160, wherein the patient is suffering from one or more of Netherton syndrome, atopic dermatitis, psoriasis, rosacea, pruritus, and peeling skin syndrome.
A method of treating Netherton syndrome, comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition comprising a serine protease inhibitor comprising a reactive site loop (RSL) of the amino acid sequence of SEQ ID NO:160, wherein the patient is suffering from Netherton syndrome.
Dependencies are inferred from the claim text.